Valuation: C4 Therapeutics, Inc.

Market Cap 418M 375M 346M 314M 586M 39.78B 593M 4.14B 1.65B 20.82B 1.57B 1.53B 66.08B P/E 2026 *
-3.99x
P/E 2027 * -3.6x
Enterprise Value 336M 302M 279M 253M 472M 32.04B 478M 3.34B 1.33B 16.76B 1.26B 1.24B 53.22B EV / Sales 2026 *
12.7x
EV / Sales 2027 * 13.5x
Free-Float
99.16%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: C4 Therapeutics, Inc.

1 day+5.76%
1 week+7.10%
Current month+1.95%
1 month+8.99%
3 months-4.37%
6 months+23.45%
Current year+77.75%
1 week 2.94
Extreme 2.94
3.53
1 month 2.59
Extreme 2.59
3.53
Current year 1.69
Extreme 1.6901
5.17
1 year 1.69
Extreme 1.6901
5.17
3 years 1.06
Extreme 1.06
11.88
5 years 1.06
Extreme 1.06
48.75
10 years 1.06
Extreme 1.06
51.21
Manager TitleAgeSince
Chief Executive Officer 55 02/10/2020
Director of Finance/CFO 49 18/09/2023
Chief Tech/Sci/R&D Officer 56 28/10/2024
Director TitleAgeSince
Director/Board Member 74 01/12/2015
Director/Board Member 55 14/09/2020
Director/Board Member 55 16/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
1/10/26 Free

Founder

3,662 0.0030%
1/10/26 Free

Director

4,618 0.0038%
18/9/26 Exercice

Chief Financial Officer

9,025 0.0073%
Change 5-day change 1-year change 3-year change Capi.($)
+5.76%+7.10%+31.59%+144.24% 395M
+0.65%-3.36%+36.98%+60.50% 63.48B
+1.76%+1.27%+11.82%+81.21% 54.55B
-0.94%+0.99%+10.45%+100.19% 53.59B
+2.76%+0.87%+27.92%+55.07% 44.75B
+2.00%-3.39%+17.83%+119.04% 41.62B
+1.34%-2.86%+224.43%+914.08% 39.91B
+0.64%-3.95%+11.15%+45.57% 32.47B
+29.06%+47.63%+107.12%+92.73% 26.7B
-2.81%-0.66%+22.91%-10.97% 23.36B
Average +4.01%+0.76%+50.22%+160.17% 38.08B
Weighted average by Cap. +2.83%+0.20%+47.98%+160.96%

Financials

2026 *2027 *
Net sales 26.4M 23.69M 21.9M 19.83M 37.05M 2.51B 37.5M 262M 104M 1.32B 99.07M 96.97M 4.18B 22.29M 19.99M 18.49M 16.74M 31.28M 2.12B 31.66M 221M 88.03M 1.11B 83.63M 81.86M 3.53B
Net income -113M -101M -93.82M -84.97M -159M -10.77B -161M -1.12B -447M -5.64B -424M -415M -17.89B -146M -131M -121M -110M -205M -13.9B -207M -1.45B -576M -7.27B -548M -536M -23.08B
Net Debt -81.29M -72.93M -67.43M -61.07M -114M -7.74B -115M -806M -321M -4.05B -305M -299M -12.86B -117M -105M -97.18M -88.01M -164M -11.16B -166M -1.16B -463M -5.84B -440M -430M -18.54B
Projected Income Statement - Annual - C4 Therapeutics, Inc.
Logo C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Employees
104
Date Price Change Volume
28/10/26 USD 3.395 +5.76% 4,108,807
27/10/26 USD 3.210 +7.72% 4,119,734
26/10/26 USD 2.980 -2.61% 3,179,137
23/10/26 USD 3.060 -3.77% 4,741,850
22/10/26 USD 3.180 +0.32% 1,692,802
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - C4 Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.395USD
Average target price
12.86USD
Spread / Average Target
+278.71%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - C4 Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CCCC Stock